MannKind reported $541.7M in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
Adma Biologics USD 191.64M 1.2M Sep/2026
BioCryst Pharmaceuticals USD 395.61M 209K Sep/2026
Eli Lilly USD 46.99B 872M Sep/2026
Halozyme Therapeutics USD 2.94B 1.01B Sep/2026
Insmed USD 544.86M 1.35M Sep/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
MacroGenics USD 163.16M 94.44M Jun/2026
MannKind USD 541.7M 3.43M Sep/2026
Merck USD 49.69B 1.39B Sep/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Novavax USD 246.3M 200K Dec/2025
Novo Nordisk DKK 18.61B 100.56B Jun/2026
Pfizer USD 60B 498M Sep/2026
Sanofi EUR 16.28B 1.63B Sep/2026
Xencor USD 71.93M 5.61M Sep/2026